What symptoms does filgotinib mainly treat?

Filgotinib(Filgotinib) is an oral small molecule JAK inhibitor. Its mechanism of action is mainly by inhibiting the Janus kinase signaling pathway, thereby regulating the release of a variety of inflammatory factors and immune responses. This mechanism makes it potentially therapeutic in a variety of chronic inflammatory diseases, especially in patient populations where traditional treatments are unsatisfactory.

In the field of rheumatoid arthritis, filgotinib is mainly used for patients with moderately to severely active RA, especially those who have poor response to treatment with methotrexate or other traditional disease-modifying antirheumatic drugs (DMARDs), or who are intolerable due to adverse reactions. By regulating inflammatory signaling pathways, filgotinib helps relieve typical symptoms such as joint pain, morning stiffness and joint swelling, and improves patients' daily activities and quality of life to a certain extent. In actual medication, it can be used as a single drug treatment or in combination with MTX or other DMARDs after physician evaluation.

In terms of ulcerative colitis, filgotinib is also used in patients with moderately to severely active disease, especially those who have insufficient response to conventional treatment options, are intolerant, or have contraindications to the drug. Its immunomodulatory effect helps reduce intestinal inflammatory response, thereby improving symptoms such as diarrhea, abdominal pain, and bloody stools. In some treatment strategies, filgotinib may be used alone or, in selected phases, in combination with corticosteroids to help control disease activity.

Generally speaking, filgotinib's main functions are focused on immune-mediated chronic inflammatory diseases. Its therapeutic goals are not limited to short-term symptom relief, but also emphasizes long-term management of disease activity. Whether the drug is suitable for use still needs to be comprehensively judged by a professional doctor based on the patient's specific condition, previous medication history, and potential risks.

Reference materials:https://www.ema.europa.eu/en/documents/product-information/jyseleca-epar-product-information_en.pdf